AbbVie (ABBV) Tops Q1 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Abbvie (ABBV) PT Raised to $129 at BMO Capital
May 3, 2021 7:31 AM EDTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $129.00 (from $127.00) while maintaining an Outperform rating.
The analyst commented, "1Q was high quality with solid top-line beat (mainly from Aesthetics and Immunology) dropping to bottom line, and improved diversification of... More
